http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Boston Scientific announces agreement to acquire SoniVie Ltd.
-
Boston Scientific announces completion of €1.5 billion offering of senior notes
-
Boston Scientific announces pricing of €1.5 billion of senior notes
-
Boston Scientific to participate in TD Cowen's 45th Annual Health Care Conference
-
Boston Scientific announces results for fourth quarter and full year 2024
-
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
-
Boston Scientific (BSX) to Acquire Bolt Medical
-
Boston Scientific Announces Agreement to Acquire Bolt Medical, Inc.
-
Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results
-
Boston Scientific (BSX) to Acquire Intera Oncology
-
Boston Scientific Announces Agreement to Acquire Intera Oncology® Inc.
-
Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial
-
Boston Scientific (BSX) Closes Acquisition of Axonics (AXNX)
-
Boston Scientific Closes Acquisition of Axonics, Inc.
-
Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference
-
Boston Scientific (BSX) to Acquire Cortex
-
Boston Scientific Announces Agreement to Acquire Cortex, Inc.
-
Boston Scientific (BSX): ACURATE neo2 Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024
-
ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024
-
Boston Scientific Announces Results for Third Quarter 2024
-
Boston Scientific (BSX) Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System
-
Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System
-
Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results
-
Boston Scientific (BSX) Receives Japanese Regulatory Approval for the FARAPULSE Pulsed Field Ablation System
-
Boston Scientific Receives Japanese Regulatory Approval for the FARAPULSE™ Pulsed Field Ablation System
-
Boston Scientific (BSX) Closes Acquisition of Silk Road Medical
-
Boston Scientific Closes Acquisition of Silk Road Medical, Inc.
-
Boston Scientific (BSX) Receives FDA Approval for Expanded Indication of INGEVITY+ Pacing Leads
-
Boston Scientific Receives FDA Approval for Expanded Indication of INGEVITY™+ Pacing Leads to Include Conduction System Pacing of the Left Bundle Branch Area
-
Boston Scientific Obtains CE Mark for ACURATE Prime™ Aortic Valve System
-
Boston Scientific to Participate in Wells Fargo's 2024 Healthcare Conference
-
Boston Scientific (BSX) Appoints David Habiger to its Board
-
Boston Scientific Elects David Habiger to Board of Directors
-
Boston Scientific Announces Results for Second Quarter 2024
-
Boston Scientific Announces Conference Call Discussing Second Quarter 2024 Results
-
Boston Scientific (BSX) to Acquire Silk Road Medical (SILK) for $27.50/sh or $1.16B
-
Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc.
-
MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints
-
Boston Scientific (BSX) Appoints Cheryl Pegus to its Board
-
Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors
-
Boston Scientific Announces Upcoming Investor Conference Schedule
-
Boston Scientific Announces Results for First Quarter 2024
-
Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module
-
Boston Scientific Announces Conference Call Discussing First Quarter 2024 Results
-
Boston Scientific (BSX) Announces FDA Approval for the AGENT Drug-Coated Balloon
-
Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon
-
Boston Scientific (BSX) Completes EUR 2B Notes Offering
-
Boston Scientific Announces Completion of €2.0 Billion Offering of Senior Notes
-
Boston Scientific (NYSE: BSX) Announces Pricing of €2.0 Billion of Senior Notes
-
Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes

